Browse studies

Find your next paid study

1 recruiting study matching your filters

A Randomized Phase 2/3 Study of Navlimetostat (BMS-986504) in Combination With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

The purpose of this study is to compare the clinical benefit of the combination of Navlimetostat (BMS-986504) (a selective MTA-cooperative inhibitor of PRMT5) …

Metastatic Non-small Cell Lung Cancer With MTAP Deletion

Estimated

~$10 – $7,500

Bristol-Myers SquibbNCT07063745